These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33431156)

  • 1. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
    Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
    Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
    Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
    Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries.
    Portnoy A; Resch SC; Suharlim C; Brenzel L; Menzies NA
    Value Health; 2021 Jan; 24(1):67-69. PubMed ID: 33431155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021-2030.
    Sriudomporn S; Watts E; Yoon Sim S; Hutubessy R; Patenaude B
    Vaccine X; 2023 Apr; 13():100256. PubMed ID: 36686400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.
    Wolfson LJ; Gasse F; Lee-Martin SP; Lydon P; Magan A; Tibouti A; Johns B; Hutubessy R; Salama P; Okwo-Bele JM
    Bull World Health Organ; 2008 Jan; 86(1):27-39. PubMed ID: 18235887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in vaccine investment in middle income countries.
    Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ
    Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Funding gap for immunization across 94 low- and middle-income countries.
    Ozawa S; Grewal S; Portnoy A; Sinha A; Arilotta R; Stack ML; Brenzel L
    Vaccine; 2016 Dec; 34(50):6408-6416. PubMed ID: 28029541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the incremental costs and savings of introducing electronic immunization registries and stock management systems: evidence from the better immunization data initiative in Tanzania and Zambia.
    Mvundura M; Di Giorgio L; Vodicka E; Kindoli R; Zulu C
    Pan Afr Med J; 2020; 35(Suppl 1):11. PubMed ID: 32373262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries.
    Munk C; Portnoy A; Suharlim C; Clarke-Deelder E; Brenzel L; Resch SC; Menzies NA
    BMC Health Serv Res; 2019 Oct; 19(1):741. PubMed ID: 31640687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study.
    Ikilezi G; Micah AE; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL
    Lancet; 2021 Nov; 398(10314):1875-1893. PubMed ID: 34742369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
    Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
    Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
    Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
    Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.
    Gandhi G; Lydon P
    BMC Public Health; 2014 Jan; 14():67. PubMed ID: 24450832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.